Researchers at the Indian Institute of Technology (IIT) Rurki have made a significant discovery, which can lead to potential treatment for chikungunya, a mosquito -borne disease that causes fever, severe joint pain, muscle pain and rashes.

According to IIT Rurki, the drug usually used for HIV treatment, Affaviranz has shown promising results in reducing the replica of chicken virus in both laboratory tests and models of mice. A study supported by the Indian Council of Medical Research (ICMR) suggests that Efavirenz can be rebuilt as an antiviral therapy for Chikungunya.

How Efaviranz works against Chikungunya

Research found that uncranges effectively reduced the levels of chikungunia virus in infected laboratory-developed cells and mice. This discovery is particularly important because there is no approved antiviral treatment for Chikungunya, which means that patients completely rely on management of symptoms such as fever and joint pain.

The study also found that Aforanz also affected the replica of the Sindbis virus, which is a virus related to Chikungunya. This suggests that the drug can have extensive antiviral properties.

Experts take conclusions

The first author of the study, Dr. Sankate Nehul reported that the affidavit appears to interfere with chikungunya virus early in its replication process. He said, “Since this drug is already widely used for HIV treatment, further clinical trials can detect their ability to chikungunya. This can help in speeding up a treatment process and can reduce the cost compared to developing a brand-new antiviral drug,” he said.

Prof. compatible author of the study. Style Tomar emphasized that current treatment for Chikungunya is limited to symptoms management. “Our research provides early scientific evidence that Ephiaranz may be a promising antiviral drug for Chikungunia, however, clinical tests will be necessary to confirm its effectiveness in patients,” he said.

Director of IIT Rurki Prof.. Kamal Kishore Pant also explains the importance of studies, stating that the institute is committed to research that suppresses public health challenges. “This study is a step ahead to address mosquito -borne viral infections,” he said.

Research has been published in a scientific magazine reviewed by a colleague, marking an important milestone. However, researchers have warned that more studies and clinical trials are required before Ephiaranz, which can be officially recommended as the treatment of chikungunya.

How to protect yourself from Chikungunia

While researchers continue to work on potential treatments, prevention remains the best defense against Chikungunia. Here are some ways to protect yourself from mosquito bites and reduce the risk of infection:

Use mosquito repellents: Apply DEET-based or natural mosquito repelles on the exposed skin, especially during the morning and evening when mosquitoes are most active.

Wear protective clothes: Opt for long -sleeved shirts, pants and socks to reduce skin contact.

Use a mosquito mesh: If you are in a high -risk area, sleep under the mosquito net to prevent cutting at night.

Remove breeding sites: Stable water empty water from flower utensils, coolers and containers where mosquitoes can lay eggs.

Install the screen and keep the window closed: Use window and door screen to prevent mosquitoes from entering your house.

Use mosquito coil or vaporizer: They can help back mosquitoes indoors, which can reduce the risk of bite.

Stay indoors during peak hours: Avoid going out during the morning and evening, when mosquitoes are most active.

As a possible treatment for Chikungunia, the discovery of affidavranges is expected, but more research is required before being widely used.

Now get the latest news with health and braking news and top headlines worldwide.